# Danaher Q3 Earnings Beat

> Danaher's new CEO pledges unambiguous share gain as earnings beat Q3 estimates with 5.5% core growth.
- Title: Danaher Q3 Earnings Beat · BigGo Finance | Shortify
- Summary: Danaher's new CEO pledges unambiguous share gain as earnings beat Q3 estimates with 5.5% core growth. Danaher raised full-year 2026 EPS guidance to…
- Keywords: danaher, julie sawyer montgomery, q3 2026, core growth, eps guidance, share gain, new ceo, respiratory testing, finance, markets, Earnings, Beat
- Source: BigGo Finance — https://finance.biggo.com/news/US_DHR_2026-10-21
- Author: BigGo Finance
- Published: 2026-10-21T14:34:24+00:00
- Read time: 1 min
- Topics: danaher, julie sawyer montgomery, q3 2026, core growth, eps guidance, share gain, new ceo, respiratory testing, finance, markets
## Danaher Q3 Results
Danaher reported third-quarter 2026 sales of $6.6 billion with core revenue growth of 3% excluding respiratory testing.
## Core Growth Accelerates
Core revenue growth accelerated to 5.5% excluding respiratory testing, a 100-basis-point increase from Q2.
## Financial Highlights
Adjusted operating margin expanded 110 basis points to 29%, and adjusted diluted EPS rose 11.5% to $2.11.
## Respiratory Testing Headwind
Respiratory revenue of about $350 million created a 250-basis-point headwind for core growth.
## New CEO's Priority
New CEO Julie Sawyer Montgomery declared unambiguous share gain as the company's 'true report card' in her first earnings call.

> unambiguous share gain is our true report card
## Q4 Guidance
Danaher guided Q4 core growth excluding respiratory of 4%-5% and set an initial 2027 framework of 4%-5%.
## Full-Year EPS Guidance
Full-year 2026 adjusted EPS guidance was raised to $8.57-$8.62 from $8.45-$8.60.
## Segment Performance
All three segments grew mid-single digits or better excluding respiratory testing with bioprocessing at the upper end.
## Bioprocessing Growth
Bioprocessing grew toward the upper end of mid-single digits with mid-teens order growth and consumables up mid-single digits.
## Diagnostics Performance
Beckman Coulter Diagnostics delivered its best quarter in over two years with new products and easing China healthcare policy.
## Respiratory Revenue Plan
Danaher plans $1.5 billion in respiratory revenue for 2026 with a $200 million 'bookend' for flu season variability.
## AI Strategy
Danaher announced an AI-powered autonomous lab and partnerships with NVIDIA and Anthropic for accelerated AI adoption.
## Capital Allocation
Masimo is described as a continuous diagnostic strategically compounding with diagnostics, not a med tech play.
## What to Watch
Investors will focus on bioprocessing order conversion, respiratory testing demand, and share gain progress in early 2027.
## Key takeaway

Danaher raised full-year 2026 EPS guidance to $8.57-$8.62 after reporting 5.5% core growth excluding respiratory testing.